Honest question
Wasn't it the FDA that reached out TO Mesoblast and not the other way round ?
"United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)"
Why would they do that ?
and doesn't that sentence above suggest that, specifically for the scenario mentioned, they are very much inviting Mesoblast to come back with the same submission ? or am I reading the tea leaves incorrectly ?
Honest questionWasn't it the FDA that reached out TO Mesoblast...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.015(1.36%) |
Mkt cap ! $1.278B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.10 | $7.169M | 6.411M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7296 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 43068 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |